Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein

Newer Version Available: 356-HV-100/CF
Formulations:

Discontinued Product

356-HV has been discontinued and is replaced by 356-HV/CF.

Product Details
Citations (2)
FAQs
Supplemental Products
Reviews

Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein Summary

Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<1.0 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to inhibit TNF-beta -mediated cytotoxicity using L‑929 mouse fibroblast cells. The ED50 for this effect is 2.5-10 µg/mL in the presence of 50 pg/mL of Recombinant Human TNF‑ beta /TNFSF1 (Catalog # 211-TB).
Source
Mouse myeloma cell line, NS0-derived human HVEM/TNFRSF14 protein
Human HVEM
Pro37-Val202
(Ser108Thr; Ala140Arg)
Accession # Q92956.3
IEGRMD Human IgG1
(Pro100-Lys330)
6-His tag
N-terminus C-terminus
Accession #
N-terminal Sequence
Analysis
Pro37
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
45 kDa (monomer)
SDS-PAGE
60 kDa, reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

356-HV

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 500 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

356-HV/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 500 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: HVEM/TNFRSF14

HVEM (herpesvirus entry mediator), also known as TNFRSF14 and CD270, is a type I membrane protein in the TNF receptor superfamily, and it can both promote and inhibit T cell activity (1). Mature human HVEM consists of a 164 amino acid (aa) extracellular domain (ECD) with three cysteine-rich domains (CRD), a 21 aa transmembrane segment, and a 60 aa cytoplasmic tail with a TRAF interaction domain (2, 3). Within the ECD, human HVEM shares 55% aa sequence identity with mouse and rat HVEM. Alternative splicing generates an additional isoform with a substitution of the N-terminal 10 amino acids including the signal peptide. HVEM is highly expressed on naïve CD4+ T cells, CD8+ T memory cells, regulatory T cells, dendritic cells, monocytes, and neutrophils (4-8). Its expression declines during effector T cell activation but is up-regulated during Treg activation (4, 5). HVEM functions as a receptor for BTLA, CD160, LIGHT/TNFSF14, and Lymphotoxin-alpha (4, 9‑12). Ligation of HVEM by LIGHT triggers T cell, monocyte, and neutrophil activation (8, 10) and contributes to Th1 inflammation and cardiac allograft rejection (13, 14). In contrast, HVEM binding to CD160 or BTLA suppresses T cell and dendritic cell activation (4, 7, 9, 10) and dampens intestinal inflammation (15). HVEM enhances the development of CD8+ T cell memory and Treg function (5, 6). It is additionally expressed on intestinal epithelial cells, where its binding by intraepithelial lymphocyte (IEL) expressed CD160 promotes epitheilal integrity and host defense (16). The herpesvirus envelope glycoprotein gD, which binds HVEM to initiate membrane fusion, can antagonize both BTLA and LIGHT binding (2, 9, 11).

References
  1. del Rio, M.L. et al. (2010) J. Leukoc. Biol. 87:223.
  2. Montgomery, R.I. et al. (1996) Cell 87:427.
  3. Hsu, H. et al. (1997) J. Biol. Chem. 272:13471.
  4. Sedy, J. R. et al. (2005) Nat. Immunol. 6:90.
  5. Tao, R. et al. (2008) J. Immunol. 180:6649.
  6. Steinberg, M.W. et al. (2013) PLoS One 8:e77992.
  7. de Trez, C. et al. (2008) J. Immunol. 180:238.
  8. Heo, S.K. et al. (2006) J. Leukoc. Biol. 79:330.
  9. Gonzalez, L.C. et al. (2005) Proc. Natl. Acad Sci. USA 102:1116.
  10. Cai, G. et al. (2008) Nat. Immunol. 9:176.
  11. Mauri, D.N. et al. (1998) Immunity 8:21.
  12. Harrop, J.A. et al. (1998) J. Biol. Chem. 273:27548.
  13. Wang, J. et al. (2005) J. Immunol. 174:8173.
  14. Ye, Q. et al. (2002) J. Exp. Med. 195:795.
  15. Steinberg, M.W. et al. (2008) J. Exp. Med. 205:1463.
  16. Shui, J.W. et al. (2012) Nature 488:222.
Long Name
Herpesvirus Entry Mediator
Entrez Gene IDs
8764 (Human); 230979 (Mouse); 102137807 (Cynomolgus Monkey)
Alternate Names
ATAR; CD270 antigen; CD270; CD40-like protein; Herpes virus entry mediator A; Herpesvirus entry mediator A; HveA; HVEM; HVEMTR2HVEAATAR; LIGHTR; TNFRSF14; tumor necrosis factor receptor superfamily member 14; tumor necrosis factor receptor superfamily, member 14 (herpesvirus entrymediator); Tumor necrosis factor receptor-like 2; tumor necrosis factor receptor-like gene2

Citations for Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

2 Citations: Showing 1 - 2
Filter your results:

Filter by:

  1. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
    Authors: El-Far, Mohamed, Pellerin, Charles, Pilote, Louise, Fortin, Jean-Fra, Lessard, Ivan A D, Peretz, Yoav, Wardrop, Elizabet, Salois, Patrick, Bethell, Richard, Cordingley, Michael, Kukolj, George
    J Transl Med, 2014;12(0):217.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy.
    Authors: Morishige T, Yoshioka Y, Inakura H, Tanabe A, Yao X, Tsunoda S, Tsutsumi Y, Mukai Y, Okada N, Nakagawa S
    Biomaterials, 2010;31(12):3357-63.
    Species: N/A
    Sample Types: Virus
    Applications: Surface Plasmon Resonance

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein

There are currently no reviews for this product. Be the first to review Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein and earn rewards!

Have you used Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review